Estrogen Therapy May Be Linked to Kidney Stones

Document Sample
Estrogen Therapy May Be Linked to Kidney Stones Powered By Docstoc
					Estrogen Therapy May Be Linked to
Kidney Stones

       Estrogen therapy may increase the risk of kidney stones in postmenopausal women, a
new study suggests.

For the study, researchers examined data on postmenopausal women in the United States,
gathered from two trials in the Women’s Health Initiative study.

One trial included 10,739 women who had had a hysterectomy, and who received either an
estrogen-only treatment or placebo, and were followed for an average of 7.1 years. The other
included 16,608 women without hysterectomy who received either estrogen plus progestin
therapy or placebo, and who were followed for an average of 5.6 years.

There were 335 cases of kidney stones reported among women in the treatment groups and 284
cases among those in the placebo groups, the investigators found. The annual kidney stone
incidence rate per 10,000 women per year was 39 in the treatment groups and 34 in the placebo
groups, according to the report in the Oct. 11 issue of the Archives of Internal Medicine.

Kidney stone development was five times more common in women who had a history of kidney
stones at the start of the trials, but development was not significantly altered by estrogen therapy,
Dr. Naim M. Maalouf, of the University of Texas Southwestern Medical Center at Dallas, and
colleagues reported.

The researchers found no significant link between kidney stone development and age, ethnicity,
body- mass index (BMI), previous hormone treatment, coffee consumption or the use of thiazide
The findings “indicate that estrogen therapy increases the risk of [kidney stones] in healthy
postmenopausal women. The mechanisms underlying this higher propensity remain to be
determined. In view of the sizable prevalence of [kidney stones] in this segment of the
population” — between 5 percent and 7 percent in the United States, according to background
information in the study — “these findings need to be considered in the decision-making process
regarding postmenopausal estrogen use,” the researchers concluded.

Shared By:
Tags: Esterogen